MannKind

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. 

CEO
Michael E. Castagna
CEOMichael E. Castagna
Employees
592
Employees592
Headquarters
Danbury, Connecticut
HeadquartersDanbury, Connecticut
Founded
1991
Founded1991
Employees
592
Employees592

MNKD Key Statistics

Market cap
1.28B
Market cap1.28B
Price-Earnings ratio
-52.95
Price-Earnings ratio-52.95
Dividend yield
Dividend yield
Average volume
4.65M
Average volume4.65M
High today
$4.23
High today$4.23
Low today
$3.98
Low today$3.98
Open price
$4.06
Open price$4.06
Volume
9.44M
Volume9.44M
52 Week high
$6.51
52 Week high$6.51
52 Week low
$2.23
52 Week low$2.23

Stock Snapshot

With a market cap of 1.28B, MannKind(MNKD) trades at $4.13. The stock has a price-to-earnings ratio of -52.95.

As of 2026-07-25, MannKind(MNKD) stock has fluctuated between $3.98 and $4.23. The current price stands at $4.13, placing the stock +3.8% above today's low and -2.4% off the high.

The MannKind(MNKD)'s current trading volume is 9.44M, compared to an average daily volume of 4.65M.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $2.23.

In the last year, MannKind(MNKD) shares hit a 52-week high of $6.51 and a 52-week low of $2.23.

MNKD News

Simply Wall St 6h
The Bull Case For MannKind Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why - simplywall.st

...

The Bull Case For MannKind Could Change Following FDA Approval Of At-Home Furoscix ReadyFlow Autoinjector – Learn Why - simplywall.st
TipRanks 13h
MannKind Raises $50 Million in Private Placement

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Benzinga 16h
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

MannKind (MNKD) Jumps On FDA Approval Of Furoscix ReadyFlow The FDA has approved Furoscix ReadyFlow, a furosemide injection designed to treat edema (swelling ca...

FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

More MNKD News

TipRanks 2d
MannKind nearing ‘underappreciated catalyst,’ says H.C. Wainwright

H.C. Wainwright views the July 26 FDA action date for the Furoscix ReadyFlow Autoinjector as an “underappreciated catalyst” for MannKind (MNKD) shares. Approval...

TipRanks 3d
MannKind’s MNKD-201 Trial: A New Inhaled Bet on Idiopathic Pulmonary Fibrosis

MannKind Corporation (MNKD) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more co...

Nasdaq 4d
What This MannKind Filing Reveals About Three Years of Underperformance

Key Points This MannKind insider filing details the disposition of 46,795 shares. The transaction reduced the insider's direct equity holdings by 9%. The act...

What This MannKind Filing Reveals About Three Years of Underperformance
Simply Wall St 6d
MannKind Stock Stays Cheap On Its 28% YTD Slump

MannKind stock has fallen 28.0% year to date, yet valuation checks suggest the market price may still sit below an estimate of intrinsic value based on a Discou...

MannKind Stock Stays Cheap On Its 28% YTD Slump

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.